Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.58 USD | -1.01% | +5.22% | +55.10% |
05-31 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
05-31 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
MarketScreener Editorial Features
ANALYST RECOMMENDATIONS : Alibaba, Goldman Sachs, Monday.com, Shaftesbury, 3M Company... | July 07, 2021 at 06:33 am |
- Stock Market
- Equities
- CALTX Stock
- CALT Stock
- News Calliditas Therapeutics AB
- MarketScreener Editorial Features